Drug Profile
Ondansetron sustained-release - Adare Pharmaceuticals
Alternative Names: EUR-1025Latest Information Update: 31 Dec 2021
Price :
$50
*
At a glance
- Originator Eurand
- Developer Adare Pharmaceuticals
- Class Anti-inflammatories; Antiemetics; Antipsychotics; Carbazoles; Drug withdrawal therapies; Imidazoles; Irritable bowel syndrome therapies; Obesity therapies; Small molecules; Smoking cessation therapies
- Mechanism of Action Serotonin 3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Nausea and vomiting
Highest Development Phases
- No development reported Nausea and vomiting
Most Recent Events
- 02 Apr 2015 Aptalis Pharmaceuticals has been acquired by TGP and renamed Adare Pharmaceuticals
- 03 Feb 2014 Aptalis has been acquired by Forest Laboratories
- 04 May 2011 Axcan is now called Aptalis